Marc Hartmann

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

Clemens von Birgelen, Marlies M. Kok, Liefke C. van der Heijden et al. · The Lancet · 2016 · 248 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Relation Between Progression and Regression of Atherosclerotic Left Main Coronary Artery Disease and Serum Cholesterol Levels as Assessed With Serial Long-Term (≥12 Months) Follow-Up Intravascular Ultrasound

Clemens von Birgelen, Marc Hartmann, Gary S. Mintz et al. · Circulation · 2003 · 153 citations

Medicine, Cardiology, Clinical Sciences +15

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial

Clemens von Birgelen, Paolo Zocca, Rosaly A. Buiten et al. · The Lancet · 2018 · 145 citations · Full text

Medicine, Cardiology, Biomaterials +15

Relationship Between Cardiovascular Risk as Predicted by Established Risk Scores Versus Plaque Progression as Measured by Serial Intravascular Ultrasound in Left Main Coronary Arteries

Clemens von Birgelen, Marc Hartmann, Gary S. Mintz et al. · Circulation · 2004 · 144 citations

Medicine, Cardiology, Clinical Cardiology +16

Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial

Liefke C. van der Heijden, Marlies M. Kok, Peter W. Danse et al. · American Heart Journal · 2016 · 78 citations · Full text

Medicine, Cardiology, Pharmacology +16